GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Bellevue Life Sciences Acquisition Corp (NAS:BLAC) » Definitions » Earnings Yield (Joel Greenblatt) %

Bellevue Life Sciences Acquisition (Bellevue Life Sciences Acquisition) Earnings Yield (Joel Greenblatt) % : -3.10% (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Bellevue Life Sciences Acquisition Earnings Yield (Joel Greenblatt) %?

Bellevue Life Sciences Acquisition's Enterprise Value for the quarter that ended in Dec. 2023 was $59.03 Mil. Bellevue Life Sciences Acquisition's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.83 Mil. Bellevue Life Sciences Acquisition's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2023 was -3.10%.

The historical rank and industry rank for Bellevue Life Sciences Acquisition's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:

BLAC' s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -4.21   Med: 0   Max: 0
Current: -3.03

BLAC's Earnings Yield (Joel Greenblatt) % is ranked worse than
62.27% of 660 companies
in the Diversified Financial Services industry
Industry Median: -1.7 vs BLAC: -3.03

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Bellevue Life Sciences Acquisition's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2023 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Bellevue Life Sciences Acquisition Earnings Yield (Joel Greenblatt) % Historical Data

The historical data trend for Bellevue Life Sciences Acquisition's Earnings Yield (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bellevue Life Sciences Acquisition Earnings Yield (Joel Greenblatt) % Chart

Bellevue Life Sciences Acquisition Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Earnings Yield (Joel Greenblatt) %
- - - -3.10

Bellevue Life Sciences Acquisition Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Earnings Yield (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - -0.34 -0.64 -1.04 -3.10

Competitive Comparison of Bellevue Life Sciences Acquisition's Earnings Yield (Joel Greenblatt) %

For the Shell Companies subindustry, Bellevue Life Sciences Acquisition's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bellevue Life Sciences Acquisition's Earnings Yield (Joel Greenblatt) % Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Bellevue Life Sciences Acquisition's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Bellevue Life Sciences Acquisition's Earnings Yield (Joel Greenblatt) % falls into.



Bellevue Life Sciences Acquisition Earnings Yield (Joel Greenblatt) % Calculation

In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.

Bellevue Life Sciences Acquisitions Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2023 is calculated as

Earnings Yield (Joel Greenblatt)=EBIT/Enterprise Value
=-1.831/59.025975
=-3.10 %

Bellevue Life Sciences Acquisition's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.83 Mil.



Bellevue Life Sciences Acquisition  (NAS:BLAC) Earnings Yield (Joel Greenblatt) % Explanation

Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.

Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.


Be Aware

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.


Bellevue Life Sciences Acquisition Earnings Yield (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Bellevue Life Sciences Acquisition's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Bellevue Life Sciences Acquisition (Bellevue Life Sciences Acquisition) Business Description

Traded in Other Exchanges
N/A
Address
10900 NE 4th Street, Suite 2300, Bellevue, WA, USA, 98004
Website
Bellevue Life Sciences Acquisition Corp is a blank check company.
Executives
David Jin Yoo officer: Chief Financial Officer (135-270) 7TH FLOOR, SOFTFORUM B/D., 545-7 DOGOKDONG, GANGNAM, SEOUL M5 135-170
Kuk Hyoun Hwang director, 10 percent owner, officer: Chief Executive Officer 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Bellevue Global Life Science Investors Llc 10 percent owner 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Steven Reed other: Director Nominee 2843-122 PL. N.E., BELLEVUE WA 98005
In Chul Chung other: Director Nominee 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Hosun Euh other: Director Nominee 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Jin Whan Park other: Director Nominee 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Jun Chul Whang director 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004
Rad Roberts other: Director Nominee 10900 NE 4TH STREET, SUITE 2300, BELLEVUE WA 98004